Business

Sage Therapeutics Discontinues Parkinson's Drug Following Mid-Stage Trial Failure

Apr 17, 2024 1 min read

Jump to Summary

Sage Therapeutics has announced the discontinuation of its experimental drug, dalzanemdor, intended for the treatment of Parkinson's disease, after it failed to meet the primary goal in a mid-stage study. The drug, also known as SAGE-718, did not demonstrate a statistically significant difference in the Wechsler Adult Intelligence Scale Fourth Edition-IV (WAIS-IV) Coding Test score compared to placebo among patients with mild cognitive impairment due to Parkinson's disease.

Following the announcement, Sage Therapeutics' shares experienced a significant drop. Reports indicated variations in the percentage decrease, with some stating a 36% decline while others cited a 19% fall in premarket trading.

The company, which had previously faced a setback with the U.S. health regulator's rejection of its drug Zurzuvae for clinical depression, had already reduced its workforce by approximately 40%, equating to about 188 employees. Despite the termination of dalzanemdor for Parkinson's treatment, Sage Therapeutics is continuing to explore the drug's potential for other cognitive impairment diseases, including Alzheimer's and Huntington's disease, with topline data from Phase 2 studies expected later in the year.

#health #finance #markets #tech #biotech

Summary

Other news in business

Southwest Airlines Implements Poison Pill to Block Elliott Management

Southwest Airlines has adopted a shareholder rights plan, commonly referred to as a "poison pill," in response to activist investor Elliott Investment Management's push for changes at the airline, including the potential ousting of CEO Bob Jordan and chairman Gary Kelly. The plan involves issuing one

EQT to Acquire Keywords Studios in £2.1 Billion Deal

Keywords Studios, a Dublin-based video game services company, has agreed to be acquired by European private equity firm EQT in a deal valued at approximately £2.1 billion ($2.5 billion). The acquisition price of 2,450 pence per share represents a 66.7% premium to the company's

US Inflation Eases, But Rate Cuts Premature Warns Fed Chair Powell

Inflation in the United States is showing signs of slowing down, according to Federal Reserve Chair Jerome Powell. This development follows higher inflation readings earlier in the year. Powell highlighted that while the recent data for April and May suggests a return to a disinflationary path, it is still premature

Jollibee to Acquire Majority Stake in South Korea's Compose Coffee

Jollibee Foods Corp. (JFC), the Philippines' largest restaurant operator, is set to acquire a 70% stake in South Korea's Compose Coffee for $340 million. The deal will be executed through Jollibee's subsidiary, Jollibee Worldwide Pte. Ltd. Compose Coffee, which operates 2,612 stores in South